Journal of Natural Medicines

, Volume 66, Issue 1, pp 127–132 | Cite as

Antipsychotic property of aqueous and ethanolic extracts of Lonchocarpus cyanescens (Schumach and Thonn.) Benth. (Fabaceae) in rodents

  • Mubo A. SonibareEmail author
  • Solomon Umukoro
  • Esther T. Shonibare
Original Paper


Lonchocarpus cyanescens (LC) is a medicinal plant commonly used in combination with other recipes in the treatment of psychotic disorders in traditional medicine. This study was designed to examine whether the aqueous and ethanolic extracts of LC possess antipsychotic property in rats. The antipsychotic effects of the extracts were assessed using the amphetamine animal model of psychosis in rats. The effect of the extracts on spontaneous motor activity was also studied in the open field test in mice. The extrapyramidal side effect of catalepsy was tested based on the ability of the extracts to alter the duration of akinesia in mice placed on a vertical wrapped string. Aqueous and ethanolic extracts of LC (25–400 mg/kg, i.p.) significantly (p < 0.05) suppressed stereotyped behaviour induced by amphetamine (10.0 mg/kg, i.p.) in rats, which suggest antipsychotic activity. The extracts (25–400 mg/kg, i.p.) further produced a significant (p < 0.05) reduction in spontaneous motor activity of the animals in the open field test. However, in contrast to chlorpromazine, a typical antipsychotic, the extracts did not induce cataleptic behaviour in the animals. Preliminary phytochemical screening showed the presence of alkaloids, anthraquinones, cardiac glycosides, cyanogenetic glycosides, flavonoids, saponins, steroids and tannins in the leaves of LC. The presence of these secondary metabolites was confirmed by thin-layer chromatography. Taken together, these findings suggest that the extracts possess phytochemically active constituents with antipsychotic property. Thus, this investigation provides evidence that may justify the ethnomedicinal applications of Lonchocarpus cyanescens as the major constituent of the recipe used for the management of psychosis in Nigeria.


Lonchocarpus cyanescens Antipsychotic Spontaneous motor activity Cataleptic 


  1. 1.
    Ehmann T, Yager J, Hanson L (2004) Early psychosis: a review of the treatment literature. Child Mental Heal Policy Res Prog 7:1–52Google Scholar
  2. 2.
    Harrison P (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593–624PubMedCrossRefGoogle Scholar
  3. 3.
    Baldessarini RJ (2001) Drugs and the treatment of psychiatry and mania. In: Hardman JG, Limbird IE (eds) Goodman and Gilman, the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 175–191Google Scholar
  4. 4.
    Mullen PE (2006) Schizophrenia and violence: from correlations to preventive strategies. Adv Psychiat Treat 12:239–248CrossRefGoogle Scholar
  5. 5.
    Davis KL, Kahn RS, Grant KO, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiat 148:1474–1486PubMedGoogle Scholar
  6. 6.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235PubMedCrossRefGoogle Scholar
  7. 7.
    Isichei HU, Egbuchylam CJ (1991) The positive aspects of the traditional healing in psychiatry. West Afr J Pharmacol Drug Res 10:31–38Google Scholar
  8. 8.
    Gill LSC (1992) Ethnomedical uses of plants in Nigeria. Uniben Press, Benin City, pp 2–15Google Scholar
  9. 9.
    Vandebroek I, Calewaert J, Dejonckheere S, Sanca S, Semo L, Damme PV, Puyvelde LV, Kimpe ND (2004) Use of medicinal plants and pharmaceuticals by indigenous communities in the Bolivain Andes and Amazon. Bull WHO 82:243–250PubMedGoogle Scholar
  10. 10.
    Sonibare MA, Soladoye MO, Subuloye TO (2008) Ethnobotanical survey of antipsychotic plants in Lagos and Ogun State of Nigeria. Eur J Sci Res 19(4):634–643Google Scholar
  11. 11.
    Cardon D, Jansen PCM (2005) Philenoptera cyanescens (Schumach. &Thonn.) Roberty. In: Jansen PCM, Cardon D (eds) Plant Resources of Tropical Africa (PROTA), Wageningen, NetherlandsGoogle Scholar
  12. 12.
    Irvine FR (1961) Woody plants of Ghana. Oxford University Press, London, p 878Google Scholar
  13. 13.
    Iwu MM, Ohiri FC (1980) Anti-arthritic triterpenoids of Lonchocarpus cyanescens Benth. Can J Pharm Sci 15:39–42Google Scholar
  14. 14.
    Harborne JB (1973) Phytochemical methods: a guide to modern techniques of plant analysis. Chapman and Hall, London, p 279Google Scholar
  15. 15.
    Trease GE, Evans WC (2002) Textbook of pharmacognosy, 20th edn. Baillière Tindall, London, pp 127–488Google Scholar
  16. 16.
    Bourin M, Poisson L, Larousse C (1986) Piracetam interaction with neuroleptics in psychopharmacological tests. Neuropsychobiology 19:93–96CrossRefGoogle Scholar
  17. 17.
    Swiergiel AH, Dunn AJ (2007) Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacol Biochem Behav 86:651–659PubMedCrossRefGoogle Scholar
  18. 18.
    Zetler G (1981) Central depressant effects of caerulein and cholecystokinin octapeptide (CCK8) differ from those of diazepam and haloperidol. Neuropharmacology 20:277–283PubMedCrossRefGoogle Scholar
  19. 19.
    Szechtman H (1986) Behavior performed at onset of drug action and apomorphine stereotypy. Eur J Pharmacol 121:49–56PubMedCrossRefGoogle Scholar
  20. 20.
    Palit G, Malsotra A, Kumar R, Nath C, Dubey MP (2001) Behavioural and antipsychotic effects of calcium channel blockers in Rhesus monkey. Eur J Pharmacol 412:139–144PubMedCrossRefGoogle Scholar
  21. 21.
    Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiat 27:1071–1079CrossRefGoogle Scholar
  22. 22.
    Nieto-Sampedro M, Shelton D, Cotman CW (1980) Specific binding of kainic acid to purified subcellular fractions from rat brain. Neurochem Res 5:591–604PubMedCrossRefGoogle Scholar
  23. 23.
    Calderon-Montaño JM, Burgos-Moron E, Perez-Guerrero C, Lopez-Lazaro M (2011) A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 11:298–344PubMedCrossRefGoogle Scholar
  24. 24.
    Aguirre-Hernandez E, Gonzalez-Trujano ME, Martinez AL, Moreno J, Kite G, Terrazas T, Soto-Hernandez M (2010) HPLC/MS analysis and anxiolytic-like effect of quercetin and kaempferol flavonoids from Tilia americana var. mexicana. J Ethnopharmacol 127:91–97PubMedCrossRefGoogle Scholar
  25. 25.
    Shopsin M, Klein H, Aaronson M, Collora M (1979) Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiat 36:657–664PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer 2011

Authors and Affiliations

  • Mubo A. Sonibare
    • 1
    Email author
  • Solomon Umukoro
    • 2
  • Esther T. Shonibare
    • 1
  1. 1.Department of Pharmacognosy, Faculty of PharmacyUniversity of IbadanIbadanNigeria
  2. 2.Department of Pharmacology and Therapeutics, Faculty of Basic Medical SciencesUniversity of IbadanIbadanNigeria

Personalised recommendations